Adult polycystic ovary syndrome begins in childhood

被引:88
作者
Franks, S [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Inst Reprod & Dev Biol, Dept Reprod Sci & Med, London W12 0NN, England
关键词
polycystic ovary syndrome; androgens; insulin resistance; type; 2; diabetes;
D O I
10.1053/beem.2002.0203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polycystic ovary syndrome (PCOS) frequently presents during adolescence and is the commonest cause of menstrual irregularity and hirsutism. The characteristic endocrine abnormalities include hypersecretion of androgens and LH. Metabolic dysfunction is also a feature of many young women with PCOS. Hyperinsulinaemia and insulin resistance, which can be regarded as an exaggeration of the normal metabolic changes that occur during puberty, are further amplified by obesity. The aetiology of PCOS is uncertain but there is evidence for a primary abnormality of ovarian androgen production which is manifest at puberty but may have its origins in childhood or even during fetal development.
引用
收藏
页码:263 / 272
页数:10
相关论文
共 37 条
[1]   Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys [J].
Abbott, DH ;
Dumesic, DA ;
Eisner, JR ;
Colman, RJ ;
Kemnitz, JW .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (02) :62-67
[2]   OVARIAN HYPERANDROGYNISM AS A RESULT OF CONGENITAL ADRENAL VIRILIZING DISORDERS - EVIDENCE FOR PERINATAL MASCULINIZATION OF NEUROENDOCRINE FUNCTION IN WOMEN [J].
BARNES, RB ;
ROSENFIELD, RL ;
EHRMANN, DA ;
CARA, JF ;
CUTTLER, L ;
LEVITSKY, LL ;
ROSENTHAL, IM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (05) :1328-1333
[3]   PITUITARY OVARIAN RESPONSES TO NAFARELIN TESTING IN THE POLYCYSTIC OVARY SYNDROME [J].
BARNES, RB ;
ROSENFIELD, RL ;
BURSTEIN, S ;
EHRMANN, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (09) :559-565
[4]  
Birch R, 2001, END ABSTR, V2, P74
[5]  
BRIDGES NA, 1993, FERTIL STERIL, V60, P456
[6]   STEROID-SECRETION IN POLYCYSTIC OVARIAN DISEASE AFTER OVARIAN SUPPRESSION BY A LONG-ACTING GONADOTROPIN-RELEASING HORMONE AGONIST [J].
CHANG, RJ ;
LAUFER, LR ;
MELDRUM, DR ;
DEFAZIO, J ;
LU, JKH ;
VALE, WW ;
RIVIER, JE ;
JUDD, HL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (05) :897-903
[7]   COMPARATIVE EFFECTS OF CYPROTERONE-ACETATE OR A LONG-ACTING GONADOTROPIN-RELEASING-HORMONE AGONIST IN POLYCYSTIC OVARIAN DISEASE [J].
COUZINET, B ;
LESTRAT, N ;
BRAILLY, S ;
SCHAISON, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (04) :1031-1035
[8]  
DAHLGREN E, 1992, FERTIL STERIL, V57, P505
[9]   Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis [J].
Dunaif, A .
ENDOCRINE REVIEWS, 1997, 18 (06) :774-800
[10]   POLYCYSTIC-OVARY-SYNDROME AS A FORM OF FUNCTIONAL OVARIAN HYPERANDROGENISM DUE TO DYSREGULATION OF ANDROGEN SECRETION [J].
EHRMANN, DA ;
BARNES, RB ;
ROSENFIELD, RL .
ENDOCRINE REVIEWS, 1995, 16 (03) :322-353